Skip to content
Search

Latest Stories

Four out of every five pharmacies can now check script exemption in real time, NHSBSA confirms

More than 80 per cent of pharmacy organizations have received the Department for Work and Pensions (DWP) functionality for Real Time Exemption Checking (RTEC).

The NHS Business Services Authority (NHSBSA) has confirmed RTEC has been rolled out gradually, in phases. Contractors first received RTEC for use with processing NHSBSA exemptions.


RTEC allows pharmacy teams to digitally check if patients are eligible for free NHS prescriptions because they hold a specific exemption. The rollout of the DWP inclusion in RTEC means patients found to be exempt via RTEC no longer need to complete an exemption declaration on an EPS token, saving time for patients and pharmacy teams.

David Broome, a community pharmacy contractor in Leeds and PSNC regional representative said: “The rollout of the DWP for our pharmacy team has been a positive development, helping reduce the amount of paperwork that my team and patients have to deal with and in turn the environmental impact of our operations. Whereas I used to send my paperwork bundle to the NHSBSA in a large box, I now send this in an envelope!”

Contractors can access and confirm their acceptance of the RTEC user agreement via the RTEC registration form in the NHSBSA’s Manage Your Service (MYS) portal.

The NHSBSA and PSNC recommend that contractors who have not done so complete the RTEC registration form within MYS to avoid a delay to their PMR system supplier activating RTEC as a part of their rollout programme.

“The NHSBSA has published a short registration guide explaining how contractors can log in to MYS and confirm acceptance of the RTEC user agreement. Contractors already using RTEC also need to confirm that they accept the RTEC user agreement if they have not already done so. Pharmacy multiples can submit a bulk declaration for multiple pharmacies if they wish,” said PSNC.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less